Literature DB >> 16652317

The risk of tuberculosis in patients with cancer.

Mini Kamboj1, Kent A Sepkowitz.   

Abstract

Current US guidelines for the management of latent tuberculosis infection in cancer patients are based on studies from 1970s, yet much about cancer care has changed in the interim. In a review of our experience during the past 25 years, we found that incidence of tuberculosis varied significantly according to country of birth and cancer type. Foreign-born patients with underlying hematologic neoplasm had a tuberculosis rate 50-100 times higher than US-born patients, whereas US-born patients with an underlying solid tumor had the same tuberculosis rate as US-born persons without cancer. These findings may help guide the management of latent tuberculosis infection in persons with cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16652317     DOI: 10.1086/503917

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  45 in total

Review 1.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

2.  Gastrointestinal cancer educatinal case series: a 65 year-old female with locally advanced gastric cancer and a supraclavicular lymph node.

Authors:  Elizabeth C Smyth; Yeon Jou Lee; Ghassan Abou-Alfa; Susan Seo; Ali Shamseddine; Eileen O'Reilly; Hassan Farran; Suha Kanj; Umayya Musharrafieh; Ghassan Awar; Hassan Sibai; Vivian Strong; Manish A Shah
Journal:  J Gastrointest Cancer       Date:  2012-03

3.  Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016.

Authors:  D Bossé; T Ng; C Ahmad; A Alfakeeh; I Alruzug; J Biagi; J Brierley; P Chaudhury; S Cleary; B Colwell; C Cripps; L A Dawson; M Dorreen; E Ferland; P Galiatsatos; S Girard; S Gray; F Halwani; N Kopek; A Mahmud; G Martel; L Robillard; B Samson; M Seal; J Siddiqui; L Sideris; S Snow; M Thirwell; M Vickers; R Goodwin; R Goel; T Hsu; E Tsvetkova; B Ward; T Asmis
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

4.  Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis.

Authors:  Claudia C Dobler; Kelvin Cheung; John Nguyen; Andrew Martin
Journal:  Eur Respir J       Date:  2017-08-24       Impact factor: 16.671

5.  Analysis of Clinical Profile and Outcome of Tuberculosis in Patients with Acute Leukemia.

Authors:  Arihant Jain; Gaurav Prakash; Charanpreet Singh; Deepesh Lad; Alka Khadwal; Vikas Suri; Pankaj Malhotra; Savita Kumari; Neelam Varma; Subhash Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2017-09-12       Impact factor: 0.900

6.  E-2-[3-(3,4-dichlorophenyl)-1-oxo-2-propenyl]-3-methylquinoxaline-1,4-dioxide: a lead antitubercular agent which alters mitochondrial respiration in rat liver.

Authors:  Umashankar Das; Swagatika Das; Brian Bandy; Dennis K J Gorecki; Jonathan R Dimmock
Journal:  Eur J Med Chem       Date:  2010-07-24       Impact factor: 6.514

7.  Pulmonary Tuberculosis Versus Recurrent Chemotherapy-Induced Pneumonitis: A Clinical Dilemma.

Authors:  Gulrayz Ahmed; Muhammad W Saif
Journal:  Cureus       Date:  2017-10-04

Review 8.  Infectious Disease Complications in Patients with Cancer.

Authors:  Susan K Seo; Catherine Liu; Sanjeet S Dadwal
Journal:  Crit Care Clin       Date:  2020-11-01       Impact factor: 3.598

9.  Impact of Fluoroquinolone Exposure Prior to Tuberculosis Diagnosis on Clinical Outcomes in Immunocompromised Patients.

Authors:  Ju Young Lee; Hyun Jung Lee; Yong Kyun Kim; Shinae Yu; Jiwon Jung; Yong Pil Chong; Sang-Oh Lee; Sang-Ho Choi; Tae Sun Shim; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

10.  Toxicity and adherence to treatment for latent tuberculosis infection in patients with hematologic malignancies.

Authors:  E M Sánchez-García; R Gamallo; A Blanco-Moure; M A Viejo; L Amador; L Anibarro
Journal:  Infection       Date:  2013-06-05       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.